A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic Dermatitis

Inclusion Criteria:

- Have moderate-to-severe Atopic Dermatitis (AD), as determined by all of the following:

1. EASI of 12 or more

2. Greater than or equal to 10% of body surface area involvement

3. Diagnosed with AD at least 2 years prior

- Have a history of inadequate clinical response to other eczema treatments

Exclusion Criteria:

- Females who are pregnant or nursing

- Participants who do not agree to use adequate contraception

- Are currently experiencing or have a history of:

- Skin conditions such as psoriasis or lupus erythematosus

- Skin disease that requires frequent hospitalizations or intravenous treatment

- Compromised immunity

- Serious illness that could interfere with study participation, or a clinically
important deviation in physical examination, vital sign measurements,
electrocardiograms, or abnormalities on laboratory tests

- Currently experiencing or have a history of:

- Active or latent Tuberculosis or specific immunity disorders and infections

- Malignancy or lymphoproliferative diseases in the last 5 years (or cervical,
basal or squamous skin cancer re-occurrence in the last 3 years)

- Human Immunodeficiency Virus (HIV)

- Hepatitis B, Hepatitis C, or chronic liver disease

- Have received certain types of vaccinations